|Bid||0.00 x 1200|
|Ask||0.00 x 1200|
|Day's range||166.02 - 171.42|
|52-week range||148.10 - 242.97|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2024 - 26 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||224.09|
CAMBRIDGE, Mass., November 30, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the "Largest Employer" category. This marks the third year in a row that Alnylam has taken the top spot in the Largest Employer category (> 1,000 employees).
CAMBRIDGE, Mass., November 11, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk. The study results were presented during the American Heart Association (AHA) Scientific Sessions being held in Philadelp
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Alnylam (ALNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.